Kintara Therapeutics Inc Stock

$4.41

3.08%

Nasdaq, Fri, Dec 27 2024

ISIN

US49720K1016

Symbol

KTRA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Trade

Industry

Wholesale

Overview Dividends Analysts Charts News Strategies

Kintara Therapeutics Inc Stock price

$4.41

-511.84 99.15% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.14 3.08%

ISIN

US49720K1016

Symbol

KTRA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Trade

Industry

Wholesale

Key metrics

Market capitalization	$186.47m
Enterprise Value	$191.81m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	negative
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-8.45m
Free Cash Flow (TTM) Free Cash Flow	$-7.20m
Cash position	$4.91m
EPS (TTM) EPS	$-75.23
P/E forward	negative
Short interest	9.81%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Kintara Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Kintara Therapeutics Inc forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Kintara Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Kintara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.06 0.06	0% 0% -
Gross Profit	-0.06 -0.06	0% 0% -
- Selling and Administrative Expenses	5.68 5.68	6% 6% -
- Research and Development Expense	2.66 2.66	71% 71% -
EBITDA	-8.40 -8.40	43% 43% -
- Depreciation and Amortization	0.06 0.06	0% 0% -
EBIT (Operating Income) EBIT	-8.45 -8.45	43% 43% -
Net Profit	-8.32 -8.32	43% 43% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Kintara Therapeutics Inc Stock News

Neutral

Accesswire

●

2 months ago

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer immunotherapy Lead program entering single Phase 3 accelerated approval registration trial in first half of 2025 for treatment of 1st line Merkel Cell carcinoma under Special Protocol Assessment (SPA) agreement with FDA $31 million fully-funded financing in conne...

Neutral

PRNewsWire

●

2 months ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

SAN DIEGO , Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 16, 2024. Kintara announced today that its Board of Directors (the "Board") has approved a reverse stock split of Kint...

Neutral

PRNewsWire

●

2 months ago

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

SAN DIEGO , Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-rev...

More Kintara Therapeutics Inc News

Company Profile

Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Head office	United States
CEO	James Bianco
Employees	11
Founded	2009
Website	www.tuhurabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now